Top News

Pfizer’s COVID Booster Shot Brings Back Almost Complete Protection

On October 21st, Pfizer announced that it conducted a trial involving 10000 participants. It was found out that the company’s booster shot gives almost complete protection from the virus.

Pfizer’s COVID Booster Shot Brings Back Almost Complete Protection

Pfizer said that the shot showed the effectiveness of 96.5 against the virus. It plans to submit this data to the Food and Drug Administration at the earliest. It also has plans to do the same with regulatory authorities abroad. According to the company, the study stresses the importance of administering booster shots to those eligible. All it wants to do is to offer complete protection to everyone from COVID 19.

Pfizer’s COVID Booster Shot Brings Back Almost Complete Protection

Pfizer always strives to ensure that the entire world has the vaccines. But Pfizer is of the view that booster shots have an important role to alleviate this threat of the COVID 19 pandemic. It is looking for ways to coordinate with regulatory authorities across the globe to see how they can support the administration of booster shots all over the world.

The trial mentioned above was done among people aged 16 and above. Its aim was to prove the efficacy of booster doses.

Pfizer says that this data adds up to the already existing evidence that its vaccine booster shots are capable of offering almost complete protection to the majority of people. These studies, according to the company, will have an important role in the eradication of this pandemic. And the country will be able to come back to normalcy at the earliest.

This Wednesday, the US Food and Drug Administration granted emergency use authorization to the vaccine booster shots of Johnson & Johnson and Moderna.

In September, CDC had recommended Pfizer vaccine booster shots for the following groups of people:

  • People 65 years old and above
  • Those living in care facilities
  • Those 50 and above with pre-existing health conditions
  • Those working in high-risk settings like correctional facilities, grocery stores, long-term care facilities and healthcare professionals

Here is an overview of what is happening in the field:

  • The booster shot of Janssen’s single-dose vaccine can be administered after two months of receiving its initial dose. The recipient has to be above 18 years of age.
  • All these vaccines are authorized for mixing and matching. This implies that a person can go for a different booster dose from the ones they received earlier.
  • Pfizer’s single booster dose is authorized to be administered for use after six months for those aged 18-64, for those living in high-risk settings

When it comes to side effects, the complications of booster shots are similar to those of the second dose. They are generally mild and go on their own.

Moderna’s vaccine booster shot is only half of its first and second doses. And it is offered after six months of receiving the second dose of the same.

FDA has also granted emergency authorization to the Johnson & Johnson vaccine booster shots. This, the agency did, after analyzing the immune responses of a trial in 39 people. The shot showed a considerable increase in the number of antibodies the body produces. Almost 9000 people have received two doses of the J&J vaccine in different clinical trials. None among them appeared to show any serious complications.

In the past, the Janssen vaccine was linked with a rare blood clotting disorder called thrombocytopenia syndrome. J&J vaccine recipients who happen to develop the condition show its signs after one or two weeks of receiving their shot.

FDA is fully aware that healthcare professionals will have questions with regard to booster shots. They are advised to check the fact-sheet of each of the vaccines authorized for use in the country. They should also follow the recommendations CDC offers from time to time.

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

To Top